This document is being posted for the purpose of inviting comments and suggestions on the proposals contained therein, which will then be considered by PDVAC for endorsement. Written comments proposing modifications to this text must be received
by 23 July 2021 and entered in the Comment Form and should be addressed to the Responsible Officer: Ms Erin Sparrow at sparrowe@who.int.
- WHO Preferred Product Characteristics for broadly neutralizing monoclonal antibodies for HIV prevention– Draft Version 0.1 for public consultation
- Comment Form – PPC HIV mAbs